Julia Rotow, MD

Articles

Optimizing Therapy Selection in EGFR Mutant NSCLC

July 22nd 2024

Helena A. Yu, MD, examines the patient selection criteria for potentially using osimertinib monotherapy, osimertinib plus chemotherapy, or amivantamab combined with lazertinib in the first-line treatment of advanced EGFR-mutant non-small cell lung cancer.

MARIPOSA Study Insights

July 16th 2024

Benjamin Levy, MD, initiates a discussion on the rationale behind using amivantamab and lazertinib as a first-line treatment for EGFR-mutant non-small cell lung cancer and reviews the recently presented efficacy and safety data from the MARIPOSA trial.

Osimertinib Monotherapy vs. Combination Therapy: Patient Selection in EGFR-Mutant Advanced NSCLC

July 16th 2024

The panel discusses which patients with EGFR-mutant non-small cell lung cancer (NSCLC) are more likely to receive frontline treatment with either osimertinib monotherapy or the combination of osimertinib and chemotherapy, based on individual patient characteristics and preferences.

Advancing Treatment for EGFR-Mutant Advanced NSCLC: Lessons from FLAURA2

July 8th 2024

Helena A. Yu, MD, discusses her treatment strategy for patients with EGFR-mutant non-small cell lung cancer (NSCLC), emphasizing current guidelines and standard of care, while Zosia Piotrowska, MD, MHS, examines the key efficacy and safety findings from the FLAURA2 study, which evaluated first-line osimertinib combined with chemotherapy in patients with advanced EGFR-mutant NSCLC.

Navigating Between ADCs in NSCLC

July 8th 2024

The panel examines the characteristics of patients with non-small cell lung cancer (NSCLC) without actionable alterations who might be the best candidates for frontline treatment with either sacituzumab govitecan or datopotamab deruxtecan (Dato-DXd) and identifies the persisting unmet needs for this patient population.

Exploring Dato-DXd Combinations as First-Line Therapy for Advanced NSCLC

July 2nd 2024

Julia Rotow, MD, explores the rationale, study design, and primary endpoints of the AVANZAR trial, which investigated the combination of datopotamab deruxtecan (Dato-DXd), durvalumab, and carboplatin as a first-line treatment for patients with advanced non-small cell lung cancer lacking actionable mutations, and discusses the patient population most likely to benefit from this drug combination.

Exploring the TROPION-Lung04 Study

July 2nd 2024

Benjamin Levy, MD, presents an overview of the TROPION-Lung04 study in the first-line setting, focusing on the toxicity profile and potential impact on clinical practice.

Role of Antibody-Drug Conjugates in NSCLC Treatment: Insights from EVOKE-02

June 24th 2024

Benjamin Levy, MD, leads discussion on the promising potential of antibody-drug conjugates (ADCs) in treating non-small cell lung cancer (NSCLC) with non-actionable mutations, while Helena A. Yu, MD, presents an overview of the EVOKE-02 study, emphasizing key efficacy and safety data that could significantly impact the current treatment landscape.

Treatment Strategies for NSCLC with Non-Actionable Mutations

June 24th 2024

Mark Socinski, MD; Helena A. Yu, MD; Zosia Piotrowska, MD, MHS; Julia Rotow, MD; and Benjamin Levy, MD, provide a concise overview of current first-line treatment options for non-small cell lung cancer (NSCLC), including their approaches for NSCLC with non-actionable mutations and the influence of PD-L1 tumor proportion score status on treatment choices.

Dr Rotow on the Investigation of ABBV-637 Plus Osimertinib in EGFR-Mutated NSCLC

October 27th 2023

Julia Rotow, MD, discusses results from a first-in-human phase 1 study of the EGFR-targeting, BCL-XL–inhibiting antibody-drug conjugate ABBV-637 in combination with osimertinib in patients with relapsed/refractory, EGFR-mutated non–small cell lung cancer.

Dr. Rotow on Remaining Questions With Brigatinib in ALK+ NSCLC

January 31st 2020

Julia Rotow, MD, discusses remaining questions with brigatinib in ALK-positive non­–small cell lung cancer.

Dr. Rotow on the Implications of Next-Generation ALK Inhibitors in NSCLC

January 31st 2020

Julia Rotow, MD, discusses the implications of next-generation ALK inhibitors in non–small cell lung cancer.

Dr. Rotow on First-Line Brigatinib Versus Crizotinib in ALK+ NSCLC

January 31st 2020

Julia Rotow, MD, discusses the utility of brigatinib versus crizotinib for the first-line treatment of patients with ALK-positive non

Dr. Rotow on Updated ALEX Trial Results in ALK+ NSCLC

January 17th 2020

Julia Rotow, MD, discusses updated data from the phase III ALEX trial in ALK-positive non–small cell lung cancer.

Dr. Rotow on Brigatinib Safety Profile in ALK+ NSCLC

January 2nd 2020

Julia Rotow, MD, discusses the safety profile of brigatinib in ALK-positive non–small cell lung cancer.